<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132990">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02146378</url>
  </required_header>
  <id_info>
    <org_study_id>B3461042</org_study_id>
    <nct_id>NCT02146378</nct_id>
  </id_info>
  <brief_title>Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan)</brief_title>
  <official_title>Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand safety (e.g., occurrence of adverse drug
      reactions [ADRs]) and efficacy data on the long-term use of Vyndaqel Capsules (hereinafter
      referred to as Vyndaqel) in all patients who received this drug under actual use conditions
      after its marketing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Both prospective and retrospective is acceptable All the patients whom an investigator
      prescribes Vyndaqel should be registered
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only</study_design>
  <primary_outcome>
    <measure>The incidence of adverse drug reaction in this study</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on the following scale; NIS, QOL-DN, mBMI</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Transthyretin Familial Amyloid Poluneuropathy</condition>
  <arm_group>
    <arm_group_label>Vyndaqel</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vyndaqel</intervention_name>
    <description>20mg/day</description>
    <arm_group_label>Vyndaqel</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The subjects of this surveillance are all patients who received Vyndaqel.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The subjects of this surveillance are all patients who received Vyndaqel.

        Exclusion Criteria:

        Patients not receive Vyndaqel.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3461042&amp;StudyName=Vyndaqel%20Drug%20Use%20Investigation%20%28regulatory%20Post%20Marketing%20Commitment%20Plan%29%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>May 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
